Who discovered GHRH? Two research teams did, just 13 days apart in 1982. Roger Guillemin, Brazeau, Böhlen, Esch, Ling and Wehrenberg published first. Jean Rivier, Joachim Spiess, Michael Thorner and Wylie Vale followed with an independent paper.
GHRH, short for growth hormone-releasing hormone, is the brain's signal telling the pituitary gland to release growth hormone. The answer wasn't sitting neatly in the brain, though. Both teams reached it through rare pancreatic tumors from patients with acromegaly, a condition caused by prolonged exposure to too much growth hormone.
The problem the GHRH researchers were trying to solve
Scientists knew the hypothalamus, a small hormone-control region in the brain, directed the pituitary gland beneath it. They had also identified somatostatin, the signal that slows growth-hormone release. The matching accelerator remained elusive.
The search lasted more than two decades. Hypothalamic tissue held very little of the unknown signal, while somatostatin could mask its activity during testing. Michael Thorner's later first-person account of the discovery explains why tumor tissue changed the odds: it contained a high concentration of the releasing signal and little somatostatin.
The researchers were trying to identify a normal brain hormone. The tumors supplied an unusually abundant, misplaced version of it.
Who discovered GHRH in the two 1982 papers?
Guillemin's team at the Salk Institute worked with tissue from a pancreatic tumor in a patient with acromegaly. On November 5, 1982, Guillemin, Pierre Brazeau, Peter Böhlen, Fritz Esch, Nicholas Ling and William Wehrenberg reported a 44-amino-acid peptide in Science. A peptide is a short chain of protein building blocks. Their synthetic copy prompted growth-hormone release in laboratory testing (PMID 6812220).
On November 18, Jean Rivier, Joachim Spiess, Michael Thorner and Wylie Vale published the second paper in Nature. Rivier, Spiess and Vale were at Salk; Thorner was at the University of Virginia. Their team characterized a 40-amino-acid form from another pancreatic islet tumor and showed that the first 29 amino acids retained the hormone's full activity in their laboratory test (PMID 6292724).
The forms differed in length, but both papers landed on the same biological signal. That is why credit belongs to two teams rather than one inventor.
The papers quickly led to human data
The next question was whether synthetic GHRH would release growth hormone in people. In a 1983 Lancet study, Thorner, Rivier, Spiess, Vale and colleagues gave the 40-amino-acid form to six healthy men. Growth hormone rose within five minutes and peaked between 30 and 60 minutes; the other measured pituitary hormones did not rise (PMID 6129370).
That was a physiology experiment, not evidence for muscle gain, fat loss or longer life. Six volunteers could show that the signal worked in humans. They could not settle what long-term treatment would do.
What recognition did the discovery receive?
Guillemin had already shared the 1977 Nobel Prize with Andrew Schally for their earlier work on peptide-hormone production in the brain, including the era's work on TRH and GnRH. The Nobel record predates the GHRH papers by five years, so it was not an award for the 1982 discovery.
The publication record supplies the fairest credit: the Science paper names six researchers, and the Nature paper names four. Thorner's clinical observation and the two Salk laboratory groups each contributed a different piece of the answer.
What came from the GHRH discovery?
The active 29-amino-acid segment became sermorelin, also called GHRH(1-29)-NH2. Geref, a sermorelin treatment product for certain children with growth-hormone deficiency, was approved in 1997. Its approval was withdrawn in 2009 at the manufacturer's request; FDA later determined that the withdrawal was not for safety or effectiveness reasons (Federal Register, 2013). The sermorelin clinical-trials guide owns the evidence details, while the regulatory history explains why sermorelin is not currently FDA-approved.
Tesamorelin kept the full 44-amino-acid backbone and added a change meant to resist breakdown. FDA's approval package records Egrifta's November 10, 2010 approval for reducing excess abdominal fat in adults with HIV and lipodystrophy (FDA review documents).
CJC-1295 took the shorter GHRH idea in a longer-acting direction. In two small randomized studies in healthy adults, CJC-1295 raised average growth hormone for at least six days and IGF-1, a downstream growth signal measured in blood, for 9 to 11 days (PMID 16352683). The sermorelin and CJC-1295 comparison explains the timing difference. Ipamorelin, often paired with CJC-1295, works through a separate receptor rather than copying GHRH.
What the discovery did not settle about aging
Finding GHRH established the signal's structure and its role in prompting the pituitary to release growth hormone. It did not show that raising growth hormone in otherwise healthy adults slows aging, improves recovery or produces a predictable body-composition change. A hormone level is a biomarker, meaning a measurable sign of biological activity, not proof of a health outcome.
The descendants are not interchangeable either. Sermorelin, tesamorelin and CJC-1295 differ in structure, duration, studied populations and regulatory history. Evidence for one cannot simply be assigned to another.
Where GHRH history stands today
As of September 18, 2026, the day this article was written, an August 1 paper studied a synthetic GHRH agonist in human heart cells and a mouse model of a type of heart failure (PMID 42541513). It was preclinical work, not a human trial of sermorelin, tesamorelin, CJC-1295 or an aging treatment.
On August 24, FDA also warned an online seller that the seller's tesamorelin and other injectable peptide products lacked approved applications. The letter concerned those specific products. It did not erase the approval of branded Egrifta.
No FDA-approved sermorelin product is currently marketed—Geref's treatment product was approved in 1997 and withdrawn in 2009—and Promise's compounded sermorelin is not FDA-approved. Tesamorelin followed a different path: branded Egrifta is approved for a narrow HIV-lipodystrophy use, and only that product carries the approval. A compounded tesamorelin formulation is different from that FDA-approved product and is not FDA-approved.
A prescribed route adds an accountable clinician and a licensed U.S. compounding pharmacy to the chain. A licensed provider may still prescribe a compounded formulation; that decision is between the patient and the doctor. At Promise, a licensed provider reviews every request, and not everyone qualifies.
The useful history is simple: two teams found the same signal, later scientists built different analogues from it, and each modern product still has to be judged on its own evidence and formulation. The discovery explains the family tree. It does not make every branch equivalent.